Recent Quotes
My Watchlist
Indicators
Investor Uprising 25
Overview
News
Currencies
International
Treasuries

Genprex Inc (NQ: GNPX )

1.550 -0.140 (-8.28%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

All News about Genprex Inc

< Previous 1 2 3 4 5 6 7 Next >
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at 2022 BIO Europe Spring Investor Conference
Via Investor Brand Network
Genprex to Participate in Upcoming Investor Conference in March
From Genprex, Inc.
Via Business Wire
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Dosing of First Patient in Acclaim-1 Clinical Trial
Via Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Participate at February Investor Conferences
Via Investor Brand Network
Genprex to Present at Upcoming Investor Conferences Highlighting its Gene Therapies for Cancer and Diabetes
From Genprex, Inc.
Via Business Wire
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Positioned to Expand Oncology Programs, Further Explore Use of ONCOPREX(R) Nanoparticle Delivery System
Via Investor Brand Network
Preclinical Data Show Potential for Use of Genprex’s ONCOPREX® Nanoparticle Delivery System in Treating Colon Cancer
From Genprex, Inc.
Via Business Wire
18 Stocks Moving in Wednesday's Pre-Market Session
Gainers Exicure, Inc. (NASDAQ: XCUR) rose 41.1% to $0.23 in pre-market trading after gaining around 4% on Tuesday. Barfresh Food Group, Inc. (NASDAQ: BRFH) shares rose 31.7% to $... 
Via Benzinga
48 Biggest Movers From Yesterday
Gainers Singularity Future Technology Ltd. (NASDAQ: SGLY) shares rose 25.9% to settle at $5.01 on Thursday. MedAvail Holdings, Inc (NASDAQ: MDVL) gained 24.4% to settle at $1.58... 
Via Benzinga
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Accelerate Opening of Acclaim-1 Clinical Trial Sites
Via Investor Brand Network
Genprex to Accelerate Opening of Acclaim-1 Clinical Trial Sites for REQORSA™ Systemic Gene Therapy in Non-Small Cell Lung Cancer
From Genprex, Inc.
Via Business Wire
50 Biggest Movers From Yesterday
Gainers Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) shares surged 63.7% to settle at $2.21 on Wednesday after the company announced that in preclinical studies its lead... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Lixte Biotech Holdings (NASDAQ:LIXT) stock increased by 70.4% to $2.3 during Wednesday's regular session. Trading volume for this security as of 12:31 EST is... 
Via Benzinga
34 Stocks Moving In Wednesday's Mid-Day Session
Gainers Mainz Biomed B.V. (NASDAQ: MYNZ) shares climbed 49.7% to $15.45 after the company announced it acquired exclusive rights to novel mRNA biomarkers. Data Storage... 
Via Benzinga
Genprex to Participate in January Investor and Healthcare Conferences to Highlight Company’s Gene Therapies in Cancer and Diabetes
From Genprex, Inc.
Via Business Wire
45 Biggest Movers From Yesterday
Gainers ATA Creativity Global (NASDAQ: AACG) gained 114.3% to close at $2.55. Hoth Therapeutics, Inc. (NASDAQ: HOTH) surged 85.7% to settle at $1.30 after the company announced... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Hoth Therapeutics (NASDAQ: 
Via Benzinga
34 Stocks Moving In Tuesday's Mid-Day Session
Gainers TherapeuticsMD, Inc. (NASDAQ: TXMD) jumped 31.7% to $0.5185 after it announced that the FDA approved a low dose version of Bijuva, an oral hormone therapy to treat women... 
Via Benzinga
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Expands Oncology R&D Pipeline to Include Small Cell Lung Cancer
Via Investor Brand Network
Genprex Expands Gene Therapy Oncology Pipeline to Include Small Cell Lung Cancer
From Genprex, Inc.
Via Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Good morning, trader! It's time to kick off another day with a dive into the biggest pre-market stock movers for Tuesday! 
Via InvestorPlace
61 Biggest Movers From Yesterday
Gainers Genprex, Inc. (NASDAQ: GNPX) shares surged 167.2% to settle at $3.50 on Monday. The FDA granted Fast Track Designation for Genprex’s lead drug candidate, Reqorsa... 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Indaptus Therapeutics (NASDAQ:INDP 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Genprex (NASDAQ:GNPX) stock moved upwards by 117.5% to $2.85 during Monday's regular session. Genprex's stock is trading at a volume of 101.5 million... 
Via Benzinga
CCL Stock: Why Carnival Is Cruising Higher Despite the CDC’s Covid Call
Carnival (CCL) stock is heading higher on Monday despite recent concerns about the Covid-19 Omicron variant and CDC warnings. 
Via InvestorPlace
TSM Stock: What Investors Are Saying About the Taiwan Semiconductor Breakout Today
Taiwan Semiconductor (TSM) stock is getting a nice boost today alongside heavy trading even without any news surrounding the company today. 
Via InvestorPlace
Dow Flat as Tesla Lifts Tech, Autos
The Dow Jones Industrial Average is flat midday, as it cools off from this morning's burst higher. Both the S&P 500 Index and Nasdaq Composite are more comfortably in the black. 
Via Talk Markets
GNPX Stock: 5 Things to Know as Genprex Rockets Higher
Shares of GNPX stock are soaring higher after the FDA granted fast track designation (FTD) for the company's lead drug candidate, REQORSA. 
Via InvestorPlace
8 Top Penny Stocks to Watch Today: EVGRF, PTE, BLCT, GNPX, AFI, CELZ, AUVI, WAVE
We're diving into the top penny stocks to watch today as several names in the space see major movement on Monday alongside heavy trading. 
Via InvestorPlace
Why Genprex Shares Are Soaring Today
Genprex Inc (NASDAQ: GNPX) is trading higher Monday after the company announced it received U.S. Food and Drug Administration Fast Track Designation (FTD) for REQORSA... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.